Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00317434 · ClinicalTrials.gov registry record · Phase 1
Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer
A Phase 1 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00317434 is a Phase 1 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 12 participants.
The verdict
NCT00317434, a Phase 1 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose of Lapatinib with Carboplatin AUC 6 in patients with platinum sensitive recurrent ovarian or primary peritoneal carcinoma and to determine the nature and degree of toxicity of Lapatinib in combination with carboplatin AUC 6 in this cohort of patients.
Interventions
- DRUG lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00317434
The ClinicalTrials.gov registry entry for NCT00317434 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lapatinib is the first listed.
NCT00317434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00317434 about?
NCT00317434 is a clinical study titled "Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer". The purpose of this study is to determine the maximum tolerated dose of Lapatinib with Carboplatin AUC 6 in patients with platinum sensitive recurrent ovarian or primary peritoneal carcinoma and to determine the nature and degree of toxicity of Lapatinib in combination with carboplatin AUC 6 in this...
What is the current status of trial NCT00317434?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2005-11. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00317434?
The interventions under investigation include: lapatinib (DRUG).
Who is sponsoring clinical trial NCT00317434?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.